Mannose supplementation in PMM2-CDG

Abstract In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper “Dietary mannose supplementation in phosphomannomutase 2 deficiency (...

Full description

Bibliographic Details
Main Authors: Roman Taday, Julien H. Park, Marianne Grüneberg, Ingrid DuChesne, Janine Reunert, Thorsten Marquardt
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:https://doi.org/10.1186/s13023-021-01988-x
id doaj-f064310920a14019a2b38a80436c504c
record_format Article
spelling doaj-f064310920a14019a2b38a80436c504c2021-08-15T11:29:58ZengBMCOrphanet Journal of Rare Diseases1750-11722021-08-011611310.1186/s13023-021-01988-xMannose supplementation in PMM2-CDGRoman Taday0Julien H. Park1Marianne Grüneberg2Ingrid DuChesne3Janine Reunert4Thorsten Marquardt5Department of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterAbstract In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper “Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)” has shown that further investigation of mannose in PMM2-CDG is worthwhile alongside other treatment options and should not be dismissed off-hand without the willingness to prove or disprove it in controlled prospective clinical trials.https://doi.org/10.1186/s13023-021-01988-xPMM2Congenital disorder of glycosylationMannoseGalactoseTherapy
collection DOAJ
language English
format Article
sources DOAJ
author Roman Taday
Julien H. Park
Marianne Grüneberg
Ingrid DuChesne
Janine Reunert
Thorsten Marquardt
spellingShingle Roman Taday
Julien H. Park
Marianne Grüneberg
Ingrid DuChesne
Janine Reunert
Thorsten Marquardt
Mannose supplementation in PMM2-CDG
Orphanet Journal of Rare Diseases
PMM2
Congenital disorder of glycosylation
Mannose
Galactose
Therapy
author_facet Roman Taday
Julien H. Park
Marianne Grüneberg
Ingrid DuChesne
Janine Reunert
Thorsten Marquardt
author_sort Roman Taday
title Mannose supplementation in PMM2-CDG
title_short Mannose supplementation in PMM2-CDG
title_full Mannose supplementation in PMM2-CDG
title_fullStr Mannose supplementation in PMM2-CDG
title_full_unstemmed Mannose supplementation in PMM2-CDG
title_sort mannose supplementation in pmm2-cdg
publisher BMC
series Orphanet Journal of Rare Diseases
issn 1750-1172
publishDate 2021-08-01
description Abstract In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper “Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)” has shown that further investigation of mannose in PMM2-CDG is worthwhile alongside other treatment options and should not be dismissed off-hand without the willingness to prove or disprove it in controlled prospective clinical trials.
topic PMM2
Congenital disorder of glycosylation
Mannose
Galactose
Therapy
url https://doi.org/10.1186/s13023-021-01988-x
work_keys_str_mv AT romantaday mannosesupplementationinpmm2cdg
AT julienhpark mannosesupplementationinpmm2cdg
AT mariannegruneberg mannosesupplementationinpmm2cdg
AT ingridduchesne mannosesupplementationinpmm2cdg
AT janinereunert mannosesupplementationinpmm2cdg
AT thorstenmarquardt mannosesupplementationinpmm2cdg
_version_ 1721206806732079104